Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US.

ABSTRACT:

Importance

A platelet ADP P2Y12 receptor (P2Y12) inhibitor plus aspirin is standard therapy for patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Compared with clopidogrel, prasugrel and ticagrelor are associated with superior antiatherothrombotic effects but increased bleeding risk; with recent guideline updates, it is important to describe current treatment patterns and the role of bleeding risk in treatment choice.

Objective

To describe secular trends and determinants of initial P2Y12 inhibitor choice and switching, including deescalation (switch from prasugrel or ticagrelor to clopidogrel).

Design, setting, and participants

This retrospective cohort study used MarketScan Commercial Claims Data from 2010 to 2019 for pat

SUBMITTER: Wang Y 

PROVIDER: S-EPMC10111179 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature